Elanco’s third quarter results were well received by the market, reflecting momentum across its pet health and farm animal portfolios. Management credited strong demand for new pet health products—particularly Zenrelia and Credelio Quattro—as well as broad-based adoption in both U.S. and international markets, for driving revenue growth and margin expansion. CEO Jeff Simmons highlighted that, “efficacy is the clear driver” behind Zenrelia’s success, and emphasized that the company’s focus on differentiated innovation, supported by targeted investments in commercial infrastructure, resulted in share gains and improved profitability.
Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).
Elanco (ELAN) Q3 2026 highlights:
- Revenue $1.27 billion vs S&P analyst consensus of $1.21 billion (11.3% year-on-year growth, 4.8% beat)
- Adjusted EPS $0.27 vs S&P analyst consensus of $0.20 (32.8% beat)
- Adjusted EBITDA $243 million vs analyst estimates of $208.4 million (19.2% margin, 16.6% beat)
- Revenue guidance $1.20 billion at the midpoint for Q4 2026, above analyst estimates of $1.19 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $1.19 at the midpoint, a 4.9% increase
- EBITDA guidance $1.06 billion at the midpoint for the full year, above analyst estimates of $1.02 billion
- Operating margin 6.4%, up from 0.2% in the same quarter last year
- Constant currency revenue rose 9% year on year, in line with the same quarter last year
- Market capitalization $12.87 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Elanco’s Q3 earnings call
-
Jon Block (Stifel) asked about margin improvement sustainability and timing of reaching the 60% gross margin target. CFO Bob VanHimbergen explained margin gains stem from price, mix, and productivity, with additional improvement expected as procurement and automation ramp up.
-
Glen Santangelo (Barclays) inquired if current performance represented a peak in share gain and about the impact of declining U.S. vet visits. CEO Jeff Simmons responded that innovation and consumer willingness to spend are more predictive than vet visit trends, and that market share gains are supported by ongoing portfolio differentiation.
-
Matt Dellatorre (Goldman Sachs) sought more detail on the outlook for pet versus farm segment growth and the split between price and volume. VanHimbergen indicated pet is expected to outperform farm, with price increases reflecting perceived value from innovative products.
-
Erin Wright (Morgan Stanley) asked about inventory levels and distribution dynamics, including the impact of new retail partnerships. Simmons and VanHimbergen confirmed inventory remained steady, and that the business benefited from new distribution points beyond Costco.
-
Andrea Alfonso (UBS) requested clarification on Befrena’s initial margin impact and the nature of the Costco contract non-renewal. VanHimbergen noted Befrena will be margin-dilutive initially but should improve with scale, while Simmons said new retail partners would offset the Costco headwind.
Catalysts in upcoming quarters
In the quarters ahead, the StockStory team will track (1) the commercial rollout and adoption rate for Befrena and its impact on pet health growth, (2) execution of productivity and margin improvement initiatives under the Elanco Ascend program, and (3) continued success of new and existing products in capturing market share globally. Progress on new retail partnerships and resilience of farm animal demand will also be critical indicators.
Elanco currently trades at $25.70, up from $23.69 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
The best stocks for high-quality investors
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
